Theravance Biopharma Inc Stock

$9.38

1.19% today

Nasdaq, Feb 28, 04:50 pm CET

ISIN

KYG8807B1068

Symbol

TBPH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Theravance Biopharma Inc Stock price

$9.27

-14.65 61.25% 5Y

Nasdaq, Closing price Thu, Feb 27 2025

+0.19 2.09%

ISIN

KYG8807B1068

Symbol

TBPH

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$455.85m
Enterprise Value	$406.61m
P/E (TTM) P/E ratio	negative
EV/Sales (TTM) EV/Sales	6.32
P/S ratio (TTM) P/S ratio	7.08
P/B ratio (TTM) P/B ratio	2.46
Revenue growth (TTM) Revenue growth	12.12%
Revenue (TTM) Revenue	$64.38m
EBIT (operating result TTM) EBIT	$-42.44m
Cash position	$88.35m
EPS (TTM) EPS	$-1.15
P/E forward	negative
P/S forward	4.41
EV/Sales forward	3.94
Short interest	15.84%

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Get Started for Free Today

Theravance Biopharma Inc Stock Analysis

Unlock Scores for Free

??

4 Analysts have issued a Theravance Biopharma Inc forecast:

2x Buy

50%

2x Hold

50%

More details on Analyst Estimates Including Price Targets

4 Analysts have issued a Theravance Biopharma Inc forecast:

Buy

50%

Hold

50%

Analyst Estimates with Stock Price Targets

Financial data from Theravance Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	64 64	12% 12% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	66 66	10% 10% 102%
- Research and Development Expense	36 36	6% 6% 56%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-42 -42	20% 20% -66%
Net Profit	-56 -56	2% 2% -88%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Theravance Biopharma Inc Stock News

Neutral

Seeking Alpha

●

one day ago

Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript

Theravance Biopharma, Inc. (NASDAQ:TBPH ) Q4 2024 Earnings Conference Call February 26, 2025 5:00 PM ET Company Participants Rick Winningham – Chief Executive Officer Rhonda Farnum – Chief Business Officer Aziz Sawaf – Chief Financial officer Aine Miller – Head-Development Conference Call Participants Douglas Tsao – H.C. Wainwright Julian Harrison – BTIG David Risinger – Leerink Partners Operat...

Neutral

PRNewsWire

●

2 days ago

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 2023 1 FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26% compared with 2023 and triggering a $50 million milestone to Theravance Biopharma 2 , 3 CYPRESS study on track to enroll final pati...

Neutral

PRNewsWire

●

8 days ago

Theravance Biopharma to Participate in an Upcoming Investor Conference

DUBLIN , Feb. 20, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will present at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 at 11:50 am EST (8:50 am PST/4:50 pm GMT) and will be hosting in-person meetings with the investment community at the conference. Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events a...

More Theravance Biopharma Inc News

Company Profile

Theravance Biopharma, Inc. operates as a biopharmaceutical company. It focuses on the discovery, research, development, and commercialization of organ-selective medicines. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

Head office	Cayman Islands
CEO	Rick Winningham
Founded	2013
Website	www.theravance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now